Clinical Trial

Radiocaine Safety Study

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 11, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1, single-center, open-label study evaluating the safety, biodistribution, and radiation dosimetry of Radiocaine™, an investigational fluorine-18-labeled PET radiotracer designed to bind voltage-gated sodium channels. The study enrolls adult volunteers and aims to inform future clinical development in molecular imaging applications. Radiocaine™ is being developed as a potential diagnostic imaging agent and imaging biomarker for the localization and quantification of sodium channel activity.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-15.
Trial Details
NCT Number NCT07081217
Lead Sponsor Lutroo Imaging LLC
Collaborators: Stanford University
Conditions Healthy Subjects
Enrollment 6 participants
Start Date 2025-06-17
Primary Completion 2026-06 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-11